The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results of a phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).
 
Ru Jia
No Relationships to Disclose
 
Hai-Yan Si
No Relationships to Disclose
 
Zhi-Kuan Wang
No Relationships to Disclose
 
Guo-Chao Deng
No Relationships to Disclose
 
Nan Zhang
No Relationships to Disclose
 
Fang-Fang Liu
No Relationships to Disclose
 
Yue Shi
No Relationships to Disclose
 
Yao-Yue Zhang
No Relationships to Disclose
 
Yu-Shan Jia
No Relationships to Disclose
 
Yanrong Wang
No Relationships to Disclose
 
Meng-Jiao Fan
No Relationships to Disclose
 
Meng-Meng Miao
No Relationships to Disclose
 
Bei Zhang
No Relationships to Disclose
 
Shuang Tong
No Relationships to Disclose
 
Guang-Hai Dai
No Relationships to Disclose